Development of a large scale process for the conversion of polysialogangliosides to monosialotetrahexosylganglioside with a novel strain of Brevibacterium casei producing sialidase

Biotechnol Lett. 2007 Jun;29(6):885-9. doi: 10.1007/s10529-007-9339-0. Epub 2007 Apr 6.

Abstract

A bioconversion process of producing GM1 (monosialotetrahexosylganglioside) on an industrial scale was developed with a novel sialidase-producing strain Brevibacterium casei. The sialidase hydrolyzed polysialogangliosides to produce GM1 but did not act on GM1. When Brevibacterium casei was cultured in a synthetic medium containing crude pig brain gangliosides (10% w/v) at 30 degrees C for 24 h in a 50 l fermenter, most of the polysialogangliosides were converted to GM1. The content of GM1 was increased from 9% in crude gangliosides to 45% with 70% (w/w) yield.

MeSH terms

  • Animals
  • Brain / metabolism
  • Brevibacterium / enzymology
  • Brevibacterium / metabolism*
  • Chromatography, Thin Layer
  • Gangliosides / chemistry
  • Gangliosides / metabolism*
  • Hydrogen-Ion Concentration
  • Kinetics
  • Neuraminidase / metabolism*
  • Substrate Specificity
  • Swine
  • Temperature

Substances

  • Gangliosides
  • sialogangliosides
  • trisialoganglioside GT1
  • Neuraminidase